Wedbush Upgrades Sierra Oncology to Outperform with Price Target $4

Brokerage firm Wedbush Upgrades its rating on Sierra Oncology(SRRA). As per the latest information, Wedbush Raises the price target to $4 per share from a prior target of $3. The shares have been rated Outperform. Previously, the analysts had a Neutral rating on the shares. The rating by the stock financial advisor at Wedbush was issued on Feb 22, 2017 in a research report to their Investors and Clients.

Add Comment